机构:[1]Capital Med Univ, Beijing Anzhen Hosp, Natl Clin Res Ctr Cardiovasc Dis, Dept Cardiol, Beijing, Peoples R China首都医科大学附属安贞医院[2]Shanxi Cardiovasc Hosp, Dept Cardiol, Taiyuan, Shanxi, Peoples R China[3]Capital Med Univ, Tongren Hosp, Cardiovasc Ctr, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Beijing Univ, Clin Res Inst, Beijing, Peoples R China
Background: Whether ablation therapy reduces the risk of death and embolic events in elderly patients with atrial fibrillation (AF) remains unclear. Material/Methods: AF patients >= 65 years old receiving either catheter ablation or non-ablation therapy at 2 tertiary and 2 non- tertiary hospitals in Beijing from November 2009 to December 2012 were enrolled. Patients were followed up every 6 months for information on treatment and clinical event occurrence. A propensity score matching algorithm produced comparable 2 groups of patients treated with ablation or non-ablation. Rates of a composite of all-cause death, non-fatal stroke, and peripheral embolism were the primary outcomes. Each composite component and major bleeding were the secondary outcomes. Results: There were 596 ablated patients and 1144 patients with non-ablation therapy enrolled. Propensity score algorithm matched 347 comparable pairs of patients. Patient characteristics variables were well balanced. During 523.5 and 497.5 patient-years follow-up, respectively, ablation therapy was associated with a significant lower risk of experiencing the primary composite outcome (hazard ratio [HR]=0.40; 95% confidence interval [CI]: 0.19-0.85), all-cause death (HR=0.13 95% CI: 0.04-0.43), and major bleeding (HR=0.23; 95% CI: 0.12-0.67), without apparent heterogeneity by age, sex, and AF type, and for risk score subgroups. Conclusions: In this propensity-matched elderly sample, ablation therapy was associated with lower risk of composite out- come consisting of all-cause death, non-fatal stroke, and peripheral embolism, and therefore might be an alternative to conservative therapy.
基金:
National Key Research and Development Program of China [2016YFC0900901, 2017YFC0908803, 2018YFC1312501]; National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81530016]; Beijing Municipal Commission of Science and Technology [D151100002215003, D151100002215004]; Beijing Municipal Science & Technology CommissionBeijing Municipal Science & Technology Commission; Biosense Webster
第一作者机构:[1]Capital Med Univ, Beijing Anzhen Hosp, Natl Clin Res Ctr Cardiovasc Dis, Dept Cardiol, Beijing, Peoples R China[2]Shanxi Cardiovasc Hosp, Dept Cardiol, Taiyuan, Shanxi, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Wang Haixiong,Du Xin,Guo Lizhu,et al.Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison[J].MEDICAL SCIENCE MONITOR.2019,25:9875-9881.doi:10.12659/MSM.917755.
APA:
Wang, Haixiong,Du, Xin,Guo, Lizhu,Guo, Xueyuan,Chen, Yingwei...&Ma, Chang-Sheng.(2019).Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison.MEDICAL SCIENCE MONITOR,25,
MLA:
Wang, Haixiong,et al."Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison".MEDICAL SCIENCE MONITOR 25.(2019):9875-9881